This study reveals FGFR4 as a key driver of lipid metabolism in CRC and demonstrates that isoliquiritigenin (ISL) effectively inhibits tumor progression by targeting the FGFR4/FASN pathway. This evidence concerns the gene FASN and colorectal carcinoma.